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Adherence to treatment in bronchiectasis: a 
challenge that physiotherapists can’t ignore
Summary
The purpose of this article is 
to highlight the importance 
for physiotherapists of patient 
adherence to treatment in 
bronchiectasis. This review 
provides evidence that adherence 
is important in bronchiectasis as it 
is low and affects health outcomes. 
We also show that there are a 
number of potentially modifiable 
factors that affect adherence that 
could be targeted through adherence 
interventions. The most effective 
methods of measuring adherence or 
interventions to enhance adherence 
are not known for bronchiectasis. 
Therefore, future research should 
focus on developing accurate and 
simple methods of adherence 
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measurement for bronchiectasis 
that could be used in clinical 
practice, as well as, developing 
interventions to enhance adherence 
that are theoretically derived and 
able to be implemented as part of 
routine clinical practice.
Introduction
Patients with bronchiectasis are prescribed a 
complex treatment regimen that can include 
airway clearance techniques (ACTs) and inhaled, 
nebulised and oral medication. The British 
Thoracic Society (BTS) guidelines for non-cystic 
fibrosis (CF) bronchiectasis recommend that 
patients with bronchiectasis and a productive 
cough should be taught an ACT for routine 
use and  those with a non-productive cough 
should be taught an ACT for use during an 
exacerbation (Pasteur et al 2010). Medications 
such as oral and inhaled antibiotics, hypertonic 
saline and β2 agonists are also recommended 
for use in this population (Pasteur et al 2010), 
despite there being no licensed medications for 
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this condition. Inhaled corticosteroids are not 
recommended for use (Pasteur et al 2010) but 
approximately 80% of patients are prescribed 
this treatment (Hill et al 2012). Evidence for 
the efficacy of these recommended treatment 
interventions is lacking and recommendations 
are mostly based on data from other conditions 
and low quality data in bronchiectasis. ACTs 
are considered a ‘cornerstone of therapy’ 
(De Soyza et al 2012) but evidence of long-
term effectiveness of this treatment is not 
available. A recent review of studies on ACTs 
concluded that ACTs were safe in patients with 
bronchiectasis but that the low quality  of 
the five included studies meant that definite 
conclusions about long-term effectiveness 
could not be drawn (Lee et al 2013). The 
superiority of one ACT over another is unclear, 
but there appears to be a patient preference 
for oscillating devices compared to active 
cycle of breathing technique (ACBT) (with and 
without postural drainage) (Eaton et al 2007; 
Patterson et al 2005) and this may be due to 
the potentially reduced burden of treatment 
associated with the use of these adjuncts. 
Determining the most effective management 
strategies in bronchiectasis is a key research 
priority for this patient population (De Soyza et 
al 2012). The interest in development of new 
medical therapies for bronchiectasis is growing 
and studies exploring new treatments have 
been recently published (Altenburg et al 2013; 
Bilton et al 2013; Haworth et al 2014; Serisier 
et al 2013; Wilson et al 2013), indicating that 
new medical therapies could be on the horizon 
for this population.  To ensure that potential 
benefits of new and existing treatments are 
gained, we need to have an understanding of 
adherence to treatment.
At present, there are no high quality data on 
adherence to treatment in bronchiectasis. 
However, we know that approximately 50% 
of patients are adherent to treatments for CF, 
asthma and chronic obstructive pulmonary 
disease (COPD) (Eakin et al 2011; Gamble et al 
2009; Krigsman et al 2007). Adherence rates for 
ACTs can often be the lowest of any prescribed 
treatment in CF and this may be due to the 
high burden of this treatment (George et al 
2010). It has been shown that the prescription 
of two of more nebulised therapies and ACT 
of greater than 30 minutes is associated with 
higher treatment burden in CF (Sawicki et al 
2009). In bronchiectasis, a treatment regimen 
may involve pre-treatment with an inhaled or 
nebulised bronchodilator and/or nebulised 
hypertonic saline, and/or an ACT and/or 
nebulised therapies such as, inhaled antibiotics 
and/or inhalers. This regimen including 
preparation and cleaning of equipment is time-
consuming, taking a minimum of 45 minutes 
which may have to be repeated twice daily and 
thus, may make adherence to these treatments 
difficult. Low adherence is known to be linked 
with poorer health outcomes for patients with 
CF (Quittner et al 2014), COPD (van Boven et al 
2014) and asthma (Gamble et al 2009) and can 
be influenced by a number of factors including 
the burden of treatment (George et al 2010) 
and beliefs about the need for treatment 
(Bucks et al 2009).  The purpose of this review 
article was to highlight the importance for 
physiotherapists of patient adherence to 
treatment in bronchiectasis. Specifically this 
review explored if adherence is important in 
bronchiectasis, how to measure adherence, 
what the predictors of adherence are, how 
adherence can be improved and what future 
research is needed. The clinical implications 
and current challenges facing clinicians when 
managing adherence are also addressed. 
Why is adherence important in 
bronchiectasis? 
A search on Medline using the search terms 
‘bronchiectasis’ and ‘adherence’ demonstrates 
that there are two published studies that 
measure adherence to inhaled antibiotics in 
bronchiectasis (Gulini et al 2012; McCullough 
et al 2014a). Gulini et al (2012) reported 
that 73% of the 22 included patients were 
adherent to inhaled antibiotics. However, 
the study was very small and only explored 
adherence to one treatment type. We recently 
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completed a large, high quality study in which 
we monitored patients’ adherence to airway 
clearance, inhaled antibiotics and other 
respiratory medicines for bronchiectasis for 
one year (McCullough et al 2014a). We found 
that only 41% were adherent to ACT, 53% were 
adherent to inhaled antibiotics, 53% were 
adherent to other respiratory medicines (i.e. 
oral, nebulised and inhaled therapies) over the 
course of a year and that only 16% of patients 
were adherent to all prescribed treatments 
(McCullough et al 2014a). Adherence to ACTs 
was measured using self-report, which is known 
to over-estimate adherence  (Quittner et al 
2008; Horne & Weinman 2002) and therefore, 
even fewer patients are likely to be adherent 
than reported. 
Low adherence is known to be linked to poorer 
health outcomes in other respiratory disease 
populations (Quittner et al 2014; van Boven et 
al 2014). Our recent data show that adherence 
to ACT is associated with better Physical 
Functioning as measured by the Quality of 
Life Questionnaire-Bronchiectasis (QOL-B) 
(McCullough et al 2013; Quittner et al 2014). 
Therefore, adherence to ACT may be important 
in maintaining patients’ level of physical 
functioning. Furthermore, those who were 
adherent to inhaled antibiotics had nearly half 
as many pulmonary exacerbations annually 
compared to non-adherers (McCullough et al 
2014a). There was no effect of adherence on 
pulmonary function (McCullough et al 2014a). 
Clinical implications
Adherence monitoring is not part of routine 
care for patients with bronchiectasis. However, 
the low level of adherence demonstrated and 
the negative impacts of non-adherence on 
health outcomes in this patient population 
indicate that there is an urgent need for 
adherence to treatment to be a priority 
during clinical interactions with patients with 
bronchiectasis as it could be low adherence, 
rather than treatment failure, that could 
be leading to disease progression. By not 
considering adherence fully in our interactions 
with patients, we may prescribe increasingly 
escalating therapies which may lead to a greater 
burden of treatment, more non-adherence and 
worse outcomes for patients. Clinicians need 
to understand how to measure adherence, be 
aware of who is at risk of non-adherence and 
how to enhance adherence in this population.  
How do we measure adherence in 
bronchiectasis? 
There is presently no ‘gold standard’ measure 
of treatment adherence (Hughes 2004) and no 
detail in the literature on what can be used to 
measure adherence in bronchiectasis. Patient 
self-report is commonly used to measure 
adherence in clinical practice usually via 
questions such as ‘are there any problems 
with your treatment?’ However, this type 
of questioning is not likely to elicit a true 
representation of patients’ adherence to 
treatment. Our data shows that more patients 
self-reported adherence to inhaled antibiotics 
and other respiratory medicines compared 
to a more objective measure of adherence 
(McCullough et al 2014a). These data support 
findings in CF, in which, self-reported adherence 
elicited via questions such as the one above or 
via a validated self-report questionnaire are 
consistently shown to over-estimate adherence 
due to patients feeling ‘social pressure’ to 
please their healthcare professional (Daniels et 
al 2011; Quittner et al 2008; Horne & Weinman 
2002). 
The ideal measure to monitor adherence would 
be accurate, allow the calculation of adherence 
on a continuous scale and in real time without 
its presence altering adherence behaviour. 
Electronic monitoring of adherence to airway 
clearance, nebulisers or inhalers using chipped 
Acapella® devices, inhalers and nebulisers 
appears to be the ideal measure. New 
technologies are being developed and existing 
technology is evolving quickly to allow detailed 
monitoring of adherence. There are currently 
no chipped Acapella® devices on the market 
for use in research or clinical practice but this 
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is likely to be an area for future development. 
I-neb® nebuliser devices measure the amount 
of medication inhaled each time the device 
is used and can give long-term adherence 
data which can be downloaded directly by 
the clinician. These devices are currently 
used in CF for the inhalation of colistin and 
are able to accurately measure adherence to 
treatment for these patients in routine clinical 
practice (Daniels et al 2011). However, the 
lack of evidence for and current cost of this 
device preclude its use in most bronchiectasis 
services. Sophisticated inhaler devices are in 
development which monitor adherence to 
inhaler technique as well as the frequency of 
medication usage (Costello & Reilly 2013) but 
are not yet available in clinical practice. 
Medication possession ratios (MPR) offer a 
potential solution for adherence monitoring 
for medication that balances objectivity with 
ease of use in clinical practice. MPRs are 
calculated using data that is already available 
through patients’ general practitioners (GP) or 
pharmacists. The calculation is completed by 
totalling up the amount of medication that a 
patient was dispensed (either from their GP 
or pharmacy) over a period of time divided by 
the amount that should have been collected 
over that time period and multiplying it by 100 
to give a percentage rate (Hess et al 2006). 
This approach does not prove ingestion or 
inhalation of medication (Osterberg & Blaschke 
2005) but it does provide a maximum level of 
adherence that patients could achieve based 
on how much they had collected. These data 
are already being collected as part of routine 
care, meaning that this approach could be 
used to monitor adherence to medication in 
bronchiectasis. We have used this method to 
calculate adherence to inhaled antibiotics and 
other respiratory medicines in bronchiectasis 
(McCullough et al 2014a) and although 
completed as part of a research project, it 
would be a feasible and useful method for 
routine clinical practice. 
Clinical implications
Self-reported adherence using traditional 
clinical questioning skills is likely to lead to 
an under-estimation of the non-adherence 
problem for these patients. This could have 
subsequent effects on treatment burden and 
adherence due to escalating treatments as 
described above. Thus, there is a need for 
clinicians to be able to question patients about 
their adherence in a way that allows patients to 
be honest about their adherence and it may be 
better for clinicians to ask patients about their 
views on treatment and barriers to adherence 
rather than specifically ask about the level of 
adherence. Given the effect of adherence on 
health outcomes we have reported, monitoring 
of clinical end-points such as frequency of 
pulmonary exacerbations along with MPR 
could be used by clinicians to identify issues 
with adherence and to instigate a discussion 
about adherence. Challenging patients about 
their adherence may have implications for 
clinical relationships between patients and 
healthcare professionals if undertaken in a way 
that is confrontational. Therefore, clinicians 
may require training on how to question about 
adherence and work with patients to overcome 
barriers to adherence.  
What are the predictors of non-
adherence? 
There is no published data on predictors of 
non-adherence in bronchiectasis. However, 
we recently determined that beliefs about 
treatment were the strongest predictors of 
adherence to treatment (McCullough et al 
2013), with patients who did not believe their 
ACT was necessary less likely to be adherent. 
Patients who were concerned about the side-
effects or long-term effects of medicines were 
less likely to be adherent to those treatments. 
These data were supported in a study in which 
we asked patients about what affected their 
decisions about adherence in bronchiectasis 
(McCullough et al 2014b). In both studies, 
beliefs about treatment were consistent 
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factors affecting adherence (McCullough et al 
2013; McCullough et al 2014b); yet, these are 
not something that are routinely explored in 
clinical interactions. To be able to assess beliefs 
about treatment in bronchiectasis, we may 
need to consider the use of an assessment 
tool such as the Beliefs about Medicines 
Questionnaire (Horne et al 1999) prior to 
and following prescription of treatment, as a 
lack of perceived necessity or high concerns 
about a treatment may indicate a risk of non-
adherence.  
Age is also an independent predictor of 
adherence in bronchiectasis (McCullough 
et al 2013) and this finding was potentially 
explained in the qualitative findings, in 
which, patients recognised that younger age 
was associated with more family and work 
commitments and also, patients tended to 
have less problematic symptoms (McCullough 
et al 2014b). Younger patients could therefore 
be at risk of low adherence, in particular, for 
treatments that are time-consuming such 
as airway clearance. This finding may also 
indicate that different barriers to adherence 
exist for younger patients, meaning that any 
strategies to overcome adherence may need to 
be tailored specifically for these patients. 
Treatment burden as measured by the 
number of prescribed medications predicted 
adherence to inhaled antibiotics, (McCullough 
et al 2013) and therefore, may be an indicator 
of risk of non-adherence to these treatments. 
Patients prescribed more medications may 
be more at risk of non-adherence which may 
provide a rationale for medication review for 
these patients prior to the prescription of new 
therapies or as part of a strategy to enhance 
adherence to existing treatments.  
Clinical implications
Clinicians can use these predictors along with 
the measurement of adherence to highlight 
those patients who might be at risk of non-
adherence and thus, who to specifically 
target to explore their adherence or who 
may require more frequent monitoring. For 
example, a young patient who is prescribed 
many treatments and doesn’t believe their 
airway clearance is necessary is less likely to 
be adherent compared to an older patient with 
few treatments and a strong belief about the 
need for airway clearance. Therefore, clinicians 
could prioritise the patient who is less likely 
to adhere to prevent to long-term impact on 
this patient’s health outcomes and escalation 
of prescribed therapies. This prioritisation 
of patients will also allow clinicians to target 
adherence within their existing workload and 
clinic format.  
How can we improve adherence in 
bronchiectasis? 
There are no bronchiectasis-specific 
interventions with the primary aim of enhancing 
adherence. In other chronic respiratory 
diseases, a multitude of interventions have 
been tested including education-based 
interventions, self-management interventions, 
pharmaceutical care and telemedicine 
interventions (McCullough et al 2014c). There 
does not appear to be any consistent effect 
of any particular type of intervention on 
adherence and health outcomes in chronic 
respiratory disease which may reflect a lack 
of high quality studies, adherence frequently 
being measured as self-report and also a diverse 
range of poorly defined, non-theoretically-
based interventions being tested (McCullough 
et al 2014c). However, there is some evidence 
that interventions that can be tailored to the 
individual, such as shared decision-making and 
cognitive behavioural therapy are effective in 
asthma (Gamble et al 2011; Wilson et al 2010). 
Clinicians are already using strategies such 
as feeding back to patients about their lung 
function to reinforce adherence behaviour, 
using patient peer support in pulmonary 
rehabilitation to reinforce positive adherence 
behaviours, giving patients self-management 
action plans, using cognitive behavioural 
therapy and shared decision-making strategies 
to enhance adherence. Current guidance 
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states that for behaviour change interventions 
to be effective, they should be theoretically-
based and developed using input from all 
relevant stakeholders including patients and 
clinicians (Medical Research Council 2008). 
Therefore, this would be important to do 
for bronchiectasis rather than incorporating 
strategies which may or may not be effective. 
We have recently explored the barriers and 
motivators to adherence in bronchiectasis 
and some of the factors affecting adherence 
decision-making in bronchiectasis that 
we have described such as beliefs about 
treatment, lack of disease knowledge, low 
self-efficacy and having a good relationship 
with healthcare professionals are potentially 
modifiable factors affecting adherence that 
could be targeted through a bronchiectasis 
specific intervention (McCullough et al 2014b). 
These factors affecting adherence could 
be used to direct the choice of behaviour 
change techniques that may act directly on 
these barriers to adherence behaviour and 
thus, potentially enhance adherence (Michie 
et al 2011). However, prior to strategies to 
enhance adherence being recommended for 
use in clinical practice for bronchiectasis, these 
should undergo pilot/feasibility testing and be 
subject to evaluation in a rigorous randomised 
controlled trial. This will ensure that ineffective 
and burdensome intervention and strategies 
are not implemented into clinical practice.
Clinical implications
Clinicians should identify patients’ specific 
barriers to adherence and use these to choose 
strategies to enhance adherence to treatment. 
There is some evidence that individualised 
strategies which elicit patients’ specific barriers 
to adherence and tailor strategies to this may 
be useful to enhance adherence (Gamble et 
al 2011; Wilson et al 2010) and could be used 
in clinical practice during routine interactions 
with patients. However, implementation of 
strategies to enhance adherence may have 
potential implications for clinician workload 
and training needs, as some strategies such as 
shared decision-making can be time-consuming 
and may require extra training. 
Conclusion
This review provides evidence that adherence 
is important in bronchiectasis as it is low and 
affects health outcomes but that there are a 
number of potentially modifiable factors that 
affect adherence that could be targeted through 
adherence interventions (McCullough et al 
2013; McCullough et al 2014b; McCullough et 
al 2014c). However, the most effective methods 
of measuring adherence or interventions 
to enhance adherence are not known for 
bronchiectasis. Patients with bronchiectasis 
are already burdened with treatments; 
therefore, implementing ineffective adherence 
measurement strategies or interventions 
may further add to this management burden. 
Therefore, it will be important to implement 
strategies that are proven to be effective.
What future research is needed? 
Future research should focus on developing 
accurate and simple methods of adherence 
measurement for bronchiectasis that could be 
used in clinical practice, as well as, developing 
interventions to enhance adherence that 
are theoretically derived and able to be 
implemented as part of routine clinical practice. 
To be able to do this, clinicians need to lobby 
for research into adherence in bronchiectasis 
to be prioritised, as in CF (Bradley et al 2012), 
and for financial investments in this area of 
research. 
Key points
• Adherence is a huge problem in 
 bronchiectasis which may lead to escalating 
 therapies and greater management burden 
 for patients and clinicians. 
• Measurement of adherence is not routine 
 in clinical practice but could be implemented 
 by questioning patients about their beliefs 
 about treatment. Additionally, for inhaled, 
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 nebulised and oral medications existing 
 data collected about dispensed medications 
 could be used. 
• Predictors of adherence could be used by 
 clinicians to target those who might be at 
 risk of non-adherence.
• Factors affecting adherence could be used 
 by clinicians to choose strategies to 
 enhance adherence to treatment but the 
 most effective strategies are not currently 
 known. 
• Clinicians need to lobby for research into 
 adherence to be prioritised and for financial 
 investment in this research area.
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